Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.
Quality of Life
brachytherapy
brachytherapy with three-dimensional conformal radiation therapy
intensity-modulated radiation therapy
prostate cancer
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
02
09
2018
revised:
04
10
2018
pubmed:
24
12
2018
medline:
19
7
2019
entrez:
22
12
2018
Statut:
ppublish
Résumé
The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with 125I brachytherapy (BT), 125I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in patients who underwent BT, BT+3D-CRT, or IMRT, using the Expanded Prostate Cancer Index Composite questionnaire before treatment and at 3 and 24 months post-treatment. Multivariate analyses were conducted to determine factors associated with a minimum important difference (MID) in urinary, bowel, sexual, and hormone domain scores at 3 and 24 months post-treatment. Of 558 enrolled patients (IMRT, 123; BT, 230; and BT+3D-CRT, 205), urinary domain scores showed a MID after BT, BT+3D-CRT and IMRT at 3 months in 69%, 84% and 25% of patients, respectively, and at 24 months in 43%, 54% and 28% of patients, respectively. On multivariate analysis, BT+3D-CRT [3 months: odds ratio (OR) = 12.7; P < 0.001; 24 months: OR = 3.29; P = 0.001] and BT (3 months: OR = 6.28; P < 0.001 and 24 months: OR = 2.22; P = 0.027) were associated with more severely worsened urinary QOL than IMRT. Bowel domain scores showed a MID at 3 months after BT, BT+3D-CRT, and IMRT in 37%, 68% and 41% of patients, respectively, and at 24 months in 29%, 46% and 43% of patients, respectively. On multivariate analysis, BT+3D-CRT (3 months: OR = 4.20; P < 0.001 and 24 months: OR = 2.63; P < 0.001) and IMRT (24 months: OR = 1.98; P = 0.029) were associated with more severely worsened bowel QOL than was BT. Information about the changes in QOL outcomes associated with radiotherapy modalities could guide treatment decisions.
Identifiants
pubmed: 30576565
pii: 5255222
doi: 10.1093/jrr/rry101
pmc: PMC6430243
doi:
Substances chimiques
Hormones
0
Iodine Radioisotopes
0
Iodine-125
GVO776611R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-280Informations de copyright
© © The Author(s) 2018. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
Références
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32
pubmed: 18325680
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Jpn J Clin Oncol. 2009 Aug;39(8):502-8
pubmed: 19477898
J Clin Oncol. 2009 Aug 20;27(24):3916-22
pubmed: 19620493
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):811-7
pubmed: 19836166
Brachytherapy. 2010 Oct-Dec;9(4):300-6
pubmed: 20708440
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305
pubmed: 20708853
BJU Int. 2011 Feb;107(4):585-90
pubmed: 20804482
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5
pubmed: 22099032
BJU Int. 2014 Sep;114(3):360-7
pubmed: 24447404
Lancet Oncol. 2014 Apr;15(4):464-73
pubmed: 24581940
J Urol. 2014 Sep;192(3):868-74
pubmed: 24603102
ISRN Urol. 2014 Mar 30;2014:140654
pubmed: 25006516
Radiat Oncol. 2014 Dec 29;9:302
pubmed: 25544509
Radiother Oncol. 2015 Aug;116(2):179-84
pubmed: 26276528
Brachytherapy. 2015 Nov-Dec;14(6):766-72
pubmed: 26489923
J Urol. 2016 May;195(5):1453-1458
pubmed: 26576709
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):581-589
pubmed: 28581398